Mona Munteanu is a full-time employee of Biopredictive.
Steatohepatitis/Metabolic Liver Disease
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease†
Article first published online: 14 AUG 2008
Copyright © 2008 American Association for the Study of Liver Diseases
Volume 49, Issue 1, pages 97–105, January 2009
How to Cite
Naveau, S., Gaudé, G., Asnacios, A., Agostini, H., Abella, A., Barri-Ova, N., Dauvois, B., Prévot, S., Ngo, Y., Munteanu, M., Balian, A., Njiké-Nakseu, M., Perlemuter, G. and Poynard, T. (2009), Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology, 49: 97–105. doi: 10.1002/hep.22576
Potential conflict of interest: Thierry Poynard is the inventor of the FibroTest with a capital interest in Biopredictive the company marketing FibroTest, the royalties belonging to the French public organization Assistance Publique Hôpitaux de Paris.
- Issue published online: 28 DEC 2008
- Article first published online: 14 AUG 2008
- Accepted manuscript online: 14 AUG 2008 12:00AM EST
- Manuscript Accepted: 7 AUG 2008
- Manuscript Received: 4 MAR 2008
Additional Supporting Information may be found in the online version of this article.
|hep_22576_sm_SupTab1.doc||47K||Supplementary TableS1: Sensitivity, specificity and predictive values of scores used in paired combination or alone of significant fibrosis F≥2 and cirrhosis F=4|
|hep_22576_sm_SupTab2.doc||49K||Supplementary table S2: Survival Analysis|
|hep_22576_sm_SupTab4.doc||63K||Table ST4A: One-year survival according to baseline AshTest|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.